How Should Clinics Define and Measure Care Coordination Pilot Metrics in 2026?

What Care Coordination Pilot Metrics Should a Clinic Measure?

A care coordination pilot should measure whether coordinated care improves outcomes that matter to patients, clinicians, and the payer without creating unnecessary work or cost. For a B2B patient-pulse and care-coordination program, the most useful scorecard combines clinical results, patient experience, operational efficiency, equity, staff experience, and financial performance rather than treating app logins or completed calls as success by themselves. As of 2 October 2026, clinics should also distinguish between activity measures, such as the number of outreach attempts, and outcome measures, such as avoided emergency department visits or improved blood-pressure control. A pilot can generate substantial activity while failing to improve care, so every activity metric should have a defined connection to a clinical or operational result. Cleveland Clinic London and Bupa’s value-based cardiac care pilot illustrates the broader movement toward models in which value and measured outcomes matter, but a clinic still needs its own baseline, population, attribution rules, and follow-up period.

Also worth reading: Why Is Patient Pulse Coordination SaaS Critical for Modern Clinics? · How Do You Choose the Right Care Coordination Software for Your Clinic Network? · How Does RPM Platform Comparison Improve B2B Care Coordination?

A defensible pilot normally follows patients for at least 90 days, with 180 or 365 days preferred when evaluating utilization, disease control, or total cost. Results should be compared with a matched baseline, randomized group, or difference-in-differences design where feasible. The headline should not rely on pre/post comparisons alone because improvements may reflect seasonal changes, staffing changes, or a simultaneous quality initiative. The central question is whether the clinic can continue the intervention at acceptable cost after pilot funding ends. This makes care coordination pilot metrics a governance tool, not merely a software dashboard.

The Core Metric Set and Recommended Benchmarks

The core scorecard should contain no more than 12 to 20 measures organized around six domains: clinical quality, patient access, patient and staff experience, operational performance, equity, and financial value. Each measure needs an owner, data source, refresh frequency, denominator, exclusion rule, baseline, and target. Recommended clinical measures include blood-pressure control, HbA1c control, medication reconciliation completion, follow-up after discharge, and avoidable acute-care use. The exact target should be based on the population and recognized program standard; inventing a universal percentage would be misleading.

For illustration, a clinic might aim for a 5% relative improvement in a selected disease-control measure over six months, an 8% relative reduction in avoidable emergency department visits among high-risk members, and at least 85% successful medication reconciliation within seven days of discharge. These are planning targets, not universal evidence-based thresholds. A target of 85% reconciliation may be sensible for one discharge pathway but unrealistic for a small sample of patients with incomplete records. Likewise, a 20% reduction in readmissions could reflect only two avoided events in a 20-patient cohort, so event counts and confidence intervals should accompany percentages.

This matrix is a design choice rather than an industry rule. A narrow pilot is easier to interpret but may lack statistical power, while a network rollout can reveal site-level variation but becomes expensive and politically complex quickly. Programs such as the CMMI ACCESS 2026 outcome-based pilot and accountable care organization work show why reimbursement and quality measurement increasingly intersect, yet reported performance still depends on attribution and data quality.

How to Build a Baseline and Evaluate the Pilot

Start by defining the eligible population before selecting the technology. “High-risk” might mean two or more chronic conditions, a recent discharge, elevated HbA1c, unread messages, or a combination of clinical and social factors. Document inclusion and exclusion criteria, because changing the denominator during the pilot can manufacture apparent improvement. Capture at least 90 days of baseline data where possible and ensure that the intervention and comparison groups use the same definitions and measurement windows.

A simple interrupted time series can compare the eight weeks before implementation with the eight weeks after implementation, but it remains vulnerable to unrelated changes. Difference-in-differences compares the change among participating patients with the change among similar nonparticipants. Randomization offers stronger evidence but may be unsuitable when immediate access is necessary. Whatever design is selected, report absolute changes, relative changes, event counts, missing data, and the number of patients who actually received the intended service. A per-protocol analysis should not replace an intention-to-treat analysis because the latter better reflects what happens when a program is offered in ordinary practice.

Data quality checks should occur before performance targets are published. Reconcile encounters, laboratory results, claims, pharmacy data, and patient-reported information, while accounting for coding changes and delayed data feeds. Include a freshness standard—for example, daily patient-pulse data, weekly operational feeds, and monthly clinical results—but only promise those intervals if the implementation can sustain them. The primary endpoint should be preselected, as changing it after unfavorable results appear increases the risk of selective reporting. Secondary measures can explore mechanisms, but they should not be presented as co-primary success metrics unless the study was powered for them.

Balancing Clinical Outcomes, Patient Experience, and Staff Experience

Patient-pulse data can detect changes before routine clinical data do, but survey volume is not equivalent to meaningful feedback. Ask whether patients feel heard, know what happens next, can obtain help quickly, and understand the purpose of outreach. A response-rate target below roughly 20% may permit broad measurement, but the clinic should report the response rate and assess whether nonrespondents differ by language, age, disability, or digital access. Do not infer that silence means satisfaction. Offer phone, paper, and interpreter-supported channels so the pulse program does not measure only patients who are comfortable using digital tools.

Staff experience matters because outreach volume can overwhelm nurses and coordinators. Track completed and attempted contacts, average handling time, duplicate outreach, after-hours work, staff rating of workflow fit, and time spent resolving data problems. A target might be that no more than 10% of messages remain unanswered for more than two business days, but the appropriate threshold depends on urgency, staffing, and service commitments. A call answered in one minute but requiring three follow-up contacts should not automatically count as efficient care.

Patient and staff results should be interpreted together. Higher message volume may mean better engagement, a larger outreach workload, duplicate documentation, or all three. Likewise, a lower alert rate may reflect improved risk stratification rather than missed cases. Quarterly interviews with a small, purposive group can explain why the numbers changed, although interviews should supplement rather than replace measurable performance data. The best programs preserve a clinical review process for urgent or ambiguous signals instead of sending every alert directly to a general inbox.

Equity, Access, and Patient Safety Checks

Equity analysis should begin before launch and continue during the pilot. Compare enrollment, reach, response, clinical improvement, adverse events, and attrition by race, ethnicity, language, age, sex, disability, insurance status, neighborhood deprivation, and digital access where legally and ethically appropriate. Small subgroup counts require careful interpretation; apparent disparities can result from random variation, but they should still trigger review rather than dismissal. Equity is not achieved simply when aggregate outcomes improve, because an overall gain can conceal worsening outcomes for a smaller group.

Access measures should include outreach acceptance, successful contact, interpreter availability, appointment wait time, and successful connection to the intended service. A message completion rate of 90% can be misleading if 10% of messages are sent in a language the patient cannot read or if alerts repeatedly go to an invalid contact method. Maintain escalation rules for medication problems, acute symptoms, domestic safety concerns, and suicidal ideation, with clear responsibility for urgent situations. A patient-pulse SaaS platform should support clinical pathways; it should not be treated as an emergency service unless trained staff and suitable response procedures are genuinely available around the clock.

Safety balancing measures can include adverse medication events, delayed referrals, duplicate tests, alert-related clinical incidents, and inappropriate alert closure. Review a sample of cases each month and document whether the program identified risk that would otherwise have been missed. This review costs time but is preferable to claiming savings based only on avoided utilization estimates. If a program cannot document the clinical pathway from alert to action, its financial benefit remains speculative.

Comparing Build, Buy, and Manual Coordination Approaches

Clinics should compare coordinated software, manual outreach, and a hybrid model rather than assuming automation is superior. Manual coordination may work for a small team and highly defined population, but staff time becomes less predictable as volume rises. A dedicated care-management platform can support risk scoring, workflows, documentation, and standardized reporting, yet configuration, integration, training, and data governance may exceed the license fee. Existing electronic health record tools may already offer messaging, registries, and care-gap reports, but a separate patient-pulse product can provide faster feedback and better longitudinal experience if its interoperability is reliable.

The supplied research includes several examples of digital-health and care-model expansion, including remote patient monitoring, chronic care management, integrated primary and specialty care, and whole-person care initiatives involving social determinants of health. These examples demonstrate experimentation, not proof that every technology produces savings. A clinic should request references, inspect actual workflow, test data export, and confirm whether quoted outcomes used a comparable population and evaluation design.

Common Mistakes That Distort Pilot Results

The most common mistake is equating adoption with impact. Seats purchased, messages sent, patients enrolled, and dashboard views establish exposure, not benefit. Another error is selecting only easy-to-reach patients, which can improve the apparent response rate while excluding those with the greatest barriers. Programs should report eligible, approached, enrolled, reached, and successfully served patients as separate numbers.

Avoid attributing every concurrent improvement to the pilot. Health systems often launch several initiatives at once, and Medicare programs such as ACCESS may introduce incentives or reporting requirements that overlap with local work. Keep an implementation log covering staffing changes, new clinics, payment changes, and other major interventions. Do not calculate return on investment from gross avoided costs without subtracting licenses, implementation, interfaces, devices, training, clinical time, patient support, and measurement expenses. Claims-based savings also require a credible attribution window and comparison group.

A third mistake is locking into one vendor-defined quality score without reviewing the underlying numerator, denominator, and exclusions. A fourth is failing to assess data burden and staff fatigue. Establish a minimum viable scorecard, retire metrics that do not inform decisions, and audit whether dashboards are used in operational huddles. Finally, avoid premature celebration based on a few anecdotes. Two avoided hospital admissions may be meaningful to those patients but insufficient evidence for a financial commitment across the network.

Costs, Pricing, and the Decision to Continue or Scale

There is no responsible universal price for a care coordination pilot because scope, integration, staffing, and risk-stratification requirements vary substantially. In 2026, clinics should expect separate categories for platform fees, implementation, interface development, device or messaging costs, clinical staffing, analytics, security review, and ongoing support. Request a 12- to 18-month proposal with optional pricing disclosed and compare total operating cost rather than per-seat cost alone. A pilot that costs less than the annual value of one avoided admission may appear attractive, but that arithmetic should be treated as a scenario until reliable utilization data support it.

Set a financial threshold before launch. One possible framework is to continue only if clinical improvement meets the prespecified target, no material safety or equity signal emerges, staff workload remains within an approved range, and projected recurring value exceeds recurring cost. A return-on-investment calculation should state assumptions such as an eligible-patient count of 250, an average coordinator cost, outreach frequency, acute-event rate, and attribution period. Sensitivity analysis should show whether the result survives conservative assumptions, including delayed adoption, missing data, and only partial effect among reached patients.

If results are inconclusive, extend measurement only when missing data, small sample size, or implementation fidelity offer a credible explanation. Do not extend a pilot indefinitely because it is politically useful. Scale in controlled waves, such as 2 to 3 clinics followed by a larger deployment, and retain a comparison population when feasible. Cleveland Clinic London and Bupa’s cardiac pilot, NCQA’s advanced primary care pilot work, and Marathon Health and Lantern’s integrated-care partnership all point to continued experimentation in 2026, but local evidence—not the prestige of an initiative—should determine procurement and rollout decisions.

A 90-Day Measurement and Governance Plan

During the first 30 days, define the population, baseline, intervention, primary outcome, balancing measures, data owners, and safety escalation process. During days 31–60, test integrations, validate denominators, measure staff workflow, and conduct a limited launch with close case review. By day 90, assess reach, fidelity, data completeness, preliminary outcomes, patient feedback, incidents, and operating cost. If signals are favorable but evidence remains immature, continue to a six-month evaluation rather than declaring success based on early utilization changes.

Governance should involve clinical leadership, operations, finance, data or analytics, information security, compliance, and patient representation. Review operational measures weekly and outcome measures monthly or quarterly. Every dashboard should support a decision: change staffing, revise outreach, fix an interface, pause a pathway, scale the program, or stop it. Record decisions and responsible owners, since a measure without an action threshold is informational rather than operational.

The definitive framework is therefore simple: define the eligible population before launch, select a small set of outcomes tied to the care model, retain a credible comparison, report absolute numbers and missing data, and include safety, equity, patient experience, and staff workload. For a care coordination pilot, success is not the largest number of digital touches; it is demonstrably better care with acceptable burden, equitable reach, and sustainable economics. That standard provides a more reliable basis for procurement than a list of software features or promotional claims.